Certolizumab Pegol is Effective at Maintaining Response and Remission in Patients With Fistulising Crohn's Disease: 3-Year Results From the PRECiSE 3 Study

被引：0
|
作者：
Schreiber, Stefan
Lawrance, Ian C.
Thomsen, Ole O.
Hanauer, Stephen B.
Bloomfield, Ralph
Sandborn, William J.
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1035
引用
下载
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [31] CIMZIA (Certolizumab Pegol) is effective in the treatment of Crohn's Disease patients with open fistulas
    Schreiber, S.
    Lawranc, I
    Thomsen, O.
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S1 - S1
  • [32] Long-Term Remission With Certolizumab Pegol in Crohn's Disease: Efficacy Over 5 Years in Patients With No Prior Anti-TNF Agent Exposure (PRECiSE 3 Study)
    Sandborn, William J.
    Schwartz, David A.
    Schreiber, Stefan
    Lawrance, Ian C.
    Sen, David I.
    Lichtenstein, Gary R.
    GASTROENTEROLOGY, 2011, 140 (05) : S262 - S262
  • [33] Maintenance of response and remission rates after 18 months of treatment with certolizumab pegol in patients with active Crohn's disease
    Lichtenstein, Gary R.
    Schreiber, Stefan
    Sandbom, William J.
    Hanauer, Stephen B.
    Feagan, Brian G.
    GASTROENTEROLOGY, 2007, 132 (04) : A502 - A502
  • [34] Long-term remission with certolizumab pegol in Crohn's disease: Efficacy over 5 years in patients with no prior anti-TNF agent exposure (precise 3 study)
    Sandborn, William J.
    Schwartz, David
    Schreiber, Stefan
    Lawrance, Ian C.
    Sen, David
    Lichtenstein, Gary R.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S23 - S23
  • [35] Can We Use Objective Markers to Predict Which Crohn's Disease Patients Will Achieve Remission With Certolizumab Pegol? Testing the PRECiSE 3 Identified Predictors of Remission in a Real World Population
    Udawatta, Viyan
    Rivers, Claudia Ramos
    Click, Benjamin H.
    Hasan, Iram
    Spearman, Marshall
    Kosutic, Gordana
    Coarse, Jason
    Dunn, Michael A.
    Regueiro, Miguel
    Binion, David G.
    GASTROENTEROLOGY, 2016, 150 (04) : S802 - S803
  • [36] Disease Activity as a Predictor of Long-Term Outcomes of Treatment With Certolizumab Pegol for Active Crohn's Disease: An Analysis of the PRECiSE 3 Study
    Choi, Jennifer
    Abraham, Bincy
    Wolf, Douglas
    Colombel, Jean-Frederic
    Kosutic, Gordana
    Spearman, Marshall
    Coarse, Jason
    Sandborn, William
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S509 - S510
  • [37] Recent-onset Crohn's disease shows higher remission rates and durability of response to treatment with subcutaneous monthly certolizumab pegol: Results from an analysis of the precise 2 phase III study
    Schreiber, S.
    Colombel, J.
    Panes, J.
    Scholmerich, J.
    McColm, J.
    Sandborn, W.
    GUT, 2007, 56 : A108 - A109
  • [38] Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
    Lichtenstein, Gary R.
    Thomsen, Ole O.
    Schreiber, Stefan
    Lawrance, Ian C.
    Hanauer, Stephen B.
    Bloomfield, Ralph
    Sandborn, William J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (07) : 600 - 609
  • [39] Predictors of response in patients with active Crohn's disease treated with certolizumab pegol: A multiple regression analysis of PRECISE 2 data
    Hanauer, Stephen B.
    Schreiber, Stefan
    Thomsen, Ole O.
    Lichtenstein, Gary R.
    Bloomfield, Ralph
    Sandborn, William J.
    GASTROENTEROLOGY, 2008, 134 (04) : A489 - A490
  • [40] Certolizumab pegol efficacy is greater with more recent-onset Crohn's Disease:: PRECiSE 2 results
    Sandborn, W.
    Colombel, J.
    Panes, P.
    Schoelmerich, P.
    McColm, J.
    Schreiber, S.
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (05) : 672 - 672
12345